Your browser doesn't support javascript.
loading
Phase IIa trial of fingolimod for amyotrophic lateral sclerosis demonstrates acceptable acute safety and tolerability.
Berry, James D; Paganoni, Sabrina; Atassi, Nazem; Macklin, Eric A; Goyal, Namita; Rivner, Michael; Simpson, Ericka; Appel, Stanley; Grasso, Daniela L; Mejia, Nicte I; Mateen, Farrah; Gill, Alan; Vieira, Fernando; Tassinari, Valerie; Perrin, Steven.
Afiliação
  • Berry JD; Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School, 165 Cambridge Street, Suite 600, Boston, Massachusetts, 02114, USA.
  • Paganoni S; Department of Neurology, Harvard Medical School, Boston, Massachusetts, USA.
  • Atassi N; Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School, 165 Cambridge Street, Suite 600, Boston, Massachusetts, 02114, USA.
  • Macklin EA; Department of Neurology, Harvard Medical School, Boston, Massachusetts, USA.
  • Goyal N; Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School, 165 Cambridge Street, Suite 600, Boston, Massachusetts, 02114, USA.
  • Rivner M; Department of Neurology, Harvard Medical School, Boston, Massachusetts, USA.
  • Simpson E; Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School, 165 Cambridge Street, Suite 600, Boston, Massachusetts, 02114, USA.
  • Appel S; Department of Neurology, Harvard Medical School, Boston, Massachusetts, USA.
  • Grasso DL; Department of Neurology, University of California, Irvine, Orange, California, USA.
  • Mejia NI; Department of Neurology, Augusta University Medical Center, Augusta, Georgia, USA.
  • Mateen F; Department of Neurology, Methodist Hospital, Houston, Texas, USA.
  • Gill A; Department of Neurology, Methodist Hospital, Houston, Texas, USA.
  • Vieira F; Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School, 165 Cambridge Street, Suite 600, Boston, Massachusetts, 02114, USA.
  • Tassinari V; Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School, 165 Cambridge Street, Suite 600, Boston, Massachusetts, 02114, USA.
  • Perrin S; Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School, 165 Cambridge Street, Suite 600, Boston, Massachusetts, 02114, USA.
Muscle Nerve ; 56(6): 1077-1084, 2017 Dec.
Article em En | MEDLINE | ID: mdl-28662296
INTRODUCTION: Immune activation has been implicated in progression of amytrophic lateral sclerosis (ALS). Oral fingolimod reduces circulating lymphocytes. The objective of this phase IIa, randomized, controlled trial was to test the short-term safety, tolerability, and target engagement of fingolimod in ALS. METHODS: Randomization was 2:1 (fingolimod:placebo). Treatment duration was 4 weeks. Primary outcomes were safety and tolerability. Secondary outcomes included circulating lymphocytes and whole-blood gene expression. RESULTS: Thirty participants were randomized; 28 were administered a drug (fingolimod 18, placebo 10). No serious adverse events occurred. Adverse events were similar by treatment arm, as was study discontinuation (2 fingolimod vs. 0 placebo, with no statistical difference). Forced expiratory volume in 1 second (FEV1 ) and FEV1 /slow vital capacity changes were similar in the fingolimod and placebo arms. Circulating lymphocytes decreased significantly in the fingolimod arm (P < 0.001). Nine immune-related genes were significantly downregulated in the fingolimod arm, including forkhead box P3 (P < 0.001) and CD40 ligand (P = 0.003). DISCUSSION: Fingolimod is safe and well-tolerated and can reduce circulating lymphocytes in ALS patients. Muscle Nerve 56: 1077-1084, 2017.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Cloridrato de Fingolimode / Esclerose Lateral Amiotrófica / Imunossupressores Tipo de estudo: Clinical_trials Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Muscle Nerve Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Cloridrato de Fingolimode / Esclerose Lateral Amiotrófica / Imunossupressores Tipo de estudo: Clinical_trials Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Muscle Nerve Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Estados Unidos